{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:05:20Z","timestamp":1793171120980,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005024","name":"Beijing Postdoctoral Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110216","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:11:08Z","timestamp":1783699868000},"page":"110216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Structure-based design, synthesis, and biological evaluation of benzofuran derivatives as dual TGF-\u03b2R1 and VEGFR2 inhibitors for potent antitumor therapy"],"prefix":"10.1016","volume":"180","author":[{"given":"Liming","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.110216_bb0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110216_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157290","article-title":"Recent advances of potential antitumor agents from natural sesquiterpenoids","volume":"148","author":"He","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2026.110216_bb0015","doi-asserted-by":"crossref","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110216_bb0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0035","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"29","key":"10.1016\/j.bioorg.2026.110216_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat7061","article-title":"Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype","volume":"3","author":"Wang","year":"2018","journal-title":"Sci. Immunol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110216_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13129","article-title":"Targeting regulatory T cells in anti-PD-1\/PD-L1 cancer immunotherapy","volume":"95","author":"Zhulai","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.791272","article-title":"Transforming growth factor-beta (TGF-\u03b2) signaling in cancer-a betrayal within","volume":"13","author":"Baba","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0055","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3390\/ijms20112767","article-title":"TGF-\u03b2-mediated epithelial-mesenchymal transition and cancer metastasis","volume":"20","author":"Hao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110216_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157326","article-title":"TGF-\u03b2 signaling in cancer: mechanisms of progression and therapeutic targets","volume":"26","author":"Cecerska-Hery\u0107","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110216_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/OTT.S493643","article-title":"Exploring TGF-\u03b2 Signaling in cancer progression: prospects and therapeutic strategies","volume":"18","author":"Sheikh","year":"2025","journal-title":"Onco. Targets Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110216_bb0070","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.7150\/thno.51383","article-title":"Targeting transforming growth factor-\u03b2 signaling for enhanced cancer chemotherapy","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110216_bb0075","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/biom9110743","article-title":"A perspective on the development of TGF-\u03b2 inhibitors for cancer treatment","volume":"9","author":"Huynh","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.110216_bb0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3892\/ijmm.2021.4888","article-title":"Role and clinical significance of TGF-\u03b21 and TGF-\u03b2R1 in malignant tumors (review)","volume":"47","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110216_bb0085","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000056","article-title":"A phase 2 study of galunisertib (TGF-\u03b21 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma","volume":"10","author":"Kelley","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0090","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s10637-020-00910-9","article-title":"Phase 1b\/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma","volume":"38","author":"Wick","year":"2020","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2026.110216_bb0095","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1158\/1078-0432.CCR-21-1504","article-title":"First-in-human phase I study of a next-generation, oral, TGF\u03b2 receptor 1 inhibitor, LY3200882, in patients with advanced cancer","volume":"27","author":"Yap","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110216_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103653","article-title":"PF-06952229, a selective TGF-\u03b2-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors","volume":"9","author":"Yap","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bioorg.2026.110216_bb0105","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cac2.12589","article-title":"Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity","volume":"44","author":"Choi","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bioorg.2026.110216_bb0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS516","article-title":"A phase II double window of opportunity trial evaluating the oral TGF-beta receptor I inhibitor vactosertib in patients undergoing standard of care preoperative therapy for locally advanced esophageal adenocarcinoma","volume":"43","author":"Patell","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0115","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.18632\/oncotarget.23795","article-title":"Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-\u03b2 receptor type I inhibitor","volume":"9","author":"Yingling","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110216_bb0120","first-page":"884","article-title":"Oral TGF-\u03b2R1 inhibitor Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity","volume":"44","author":"Choi","year":"2023","journal-title":"Res. Sq."},{"key":"10.1016\/j.bioorg.2026.110216_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108211","article-title":"The roles of TGF-\u03b2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors","volume":"240","author":"Bu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.110216_bb0130","first-page":"125","article-title":"A mini review on the multifaceted role of TGF-\u03b2 in metastasis progression: molecular mechanisms and novel therapeutic strategie","volume":"2","author":"Mohammadi","year":"2025","journal-title":"Acta Biochim. Iranica"},{"key":"10.1016\/j.bioorg.2026.110216_bb0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","article-title":"Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy","volume":"16","author":"Niu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0140","article-title":"Therapeutic targeting of VEGF and\/or TGF-\u03b2 to enhance anti-PD-(L)1 therapy: the evidence from clinical trials","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0145","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/biom10121673","article-title":"Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy","volume":"10","author":"Shaik","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.110216_bb0150","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/molecules26041076","article-title":"Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR)","volume":"26","author":"Kaufman","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110216_bb0155","doi-asserted-by":"crossref","first-page":"1583329","DOI":"10.3389\/fphar.2025.1583329","article-title":"Structure-based molecular screening and dynamic simulation of phytocompounds targeting VEGFR-2: a novel therapeutic approach for papillary thyroid carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0160","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.110216_bb0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","article-title":"Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"17","author":"Chen","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0170","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2024.8","article-title":"Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness","volume":"26","author":"Mongiardi","year":"2024","journal-title":"Expert Rev. Mol. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110216_bb0175","doi-asserted-by":"crossref","first-page":"276","DOI":"10.21037\/tcr-20-3539","article-title":"Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review","volume":"11","author":"Xu","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110216_bb0180","doi-asserted-by":"crossref","first-page":"1163967","DOI":"10.3389\/fimmu.2023.1163967","article-title":"The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms","volume":"14","author":"Jiang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70279","article-title":"N-acetyl-L-cysteine (NAC) blunts axitinib-related adverse effects in preclinical models of glioblastoma","volume":"13","author":"Formato","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2026.110216_bb0190","doi-asserted-by":"crossref","first-page":"33384","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110216_bb0195","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-018-03765-3","article-title":"A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer","volume":"83","author":"Campone","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0200","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14656566.2022.2102419","article-title":"Tivozanib for the treatment of advanced renal cell carcinoma","volume":"23","author":"Chatzkel","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110216_bb0205","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41416-020-0737-6","article-title":"A multicentre phase 1b\/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma","volume":"122","author":"Fountzilas","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110216_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1010726","article-title":"Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0220","first-page":"2306","article-title":"Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110216_bb0225","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110216_bb0230","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cam4.1140","article-title":"A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF\/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status","volume":"6","author":"Izar","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2026.110216_bb0235","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1021\/ml500526p","article-title":"Discovery of RAF265: a potent Mut-B-RAF inhibitor for the treatment of metastatic melanoma","volume":"6","author":"Williams","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110216_bb0240","doi-asserted-by":"crossref","first-page":"1534707","DOI":"10.3389\/fphar.2025.1534707","article-title":"Pharmacophore screening, molecular docking, and MD simulations for identification of VEGFR-2 and c-Met potential dual inhibitors","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110216_bb0245","doi-asserted-by":"crossref","first-page":"18567","DOI":"10.1038\/s41598-023-45687-y","article-title":"Novel 3-phenylquinazolin-2,4(1H,3H)-diones as dual VEGFR-2\/c-met-TK inhibitors: design, synthesis, and biological evaluation","volume":"13","author":"Hassan","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110216_bb0250","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signaling CCS"},{"key":"10.1016\/j.bioorg.2026.110216_bb0255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/cancers16020461","article-title":"Targeted therapeutic strategies for the treatment of cancer","volume":"16","author":"Victoir","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110216_bb0260","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110216_bb0265","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1021\/jm0400247","article-title":"Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-\u03b2 type I receptor inhibitors","volume":"47","author":"Gellibert","year":"2004","journal-title":"J. Med. Chem."},{"issue":"45","key":"10.1016\/j.bioorg.2026.110216_bb0270","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"23","key":"10.1016\/j.bioorg.2026.110216_bb0275","doi-asserted-by":"crossref","first-page":"12689","DOI":"10.1080\/07391102.2023.2272751","article-title":"Integrated molecular modeling and dynamics approaches revealed the mechanism of selective inhibition of HDAC6\/8","volume":"42","author":"Li","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"37","key":"10.1016\/j.bioorg.2026.110216_bb0280","doi-asserted-by":"crossref","first-page":"24564","DOI":"10.1039\/D4CP02480J","article-title":"Discovery of a urea-based hit compound as a novel inhibitor of transforming growth factor-\u03b2 type 1 receptor: in silico and in vitro studies","volume":"26","author":"Li","year":"2024","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110216_bb0285","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110216_bb0290","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110216_bb0295","unstructured":"The PyMOL Molecular Graphics System, Version 3.0 Schr\u00f6dinger, LLC."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110216_bb0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110216_bb0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph. Model"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:36:57Z","timestamp":1787675817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":61,"alternative-id":["S0045206826007522"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110216","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design, synthesis, and biological evaluation of benzofuran derivatives as dual TGF-\u03b2R1 and VEGFR2 inhibitors for potent antitumor therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110216"}}